Hepatocyte growth factor (HGF)/Met signaling has critical roles in pancreatic ductal adenocarcinoma (PDA) development and progression and is considered a potential therapeutic target for this disease. However, the mechanism of aberrant activation of HGF/Met signaling and resistance to Met inhibition in PDA remains unclear. The mechanistic role of cross talk between Forkhead box M1 (FOXM1) and HGF/Met signaling in promotion of PDA growth and resistance to Met inhibition was examined using cell culture, molecular biology and mouse models; and the relevance of our experimental and mechanistic findings were validated using human PDA tissues. Met was markedly overexpressed in both PDA cell lines and pancreatic tumor specimens, and the expression of Met correlated directly with that of FOXM1 in human tumor specimens. Mechanistically, FOXM1 bound to the promoter region of the Met gene and transcriptionally increased the expression of Met. Increased expression of FOXM1 enhanced the activation of HGF/Met signaling and its downstream pathways, including retrovirus-associated DNA sequences/extracellular signal-regulated kinase 1/2, phosphoinositide 3-kinase/AKT and signal transducer and activator of transcription 3. Furthermore, activation of HGF/Met signaling increased the expression and transcriptional activity of FOXM1, and the cross talk between FOXM1 and HGF/Met signaling promoted PDA growth and resistance to Met inhibition. Collectively, our findings identified a positive feedback loop formed by FOXM1 and HGF/Met and revealed that this loop is a potentially effective therapeutic target for PDA.
INTRODUCTION
Pancreatic ductal adenocarcinoma (PDA), which is often just called pancreatic cancer, accounts for 490% of pancreatic cancer cases and is the seventh leading cause of cancer-related deaths worldwide, with an incidence that is increasing annually. 1, 2 Although translational research of surgery, radiation therapy, chemotherapy and molecular-targeted therapy for PDA have improved greatly, 75% of patients die within 12 months after diagnosis, and the 5-year overall survival rate is o5%. 3 Thus further studies of the molecular drivers of new therapeutic targets for PDA are urgently needed.
Met, a receptor tyrosine kinase, is predominantly expressed in epithelial and endothelial cells. Binding of Met with its ligand hepatocyte growth factor (HGF) leads to dimerization and phosphorylation at two tyrosine residues (Tyr1234 and Tyr1235) close to or within the catalytic pocket of Met. Furthermore, Met could associate and form dimerization with receptor originated from Nantes (RON), and RON ligand macrophage-stimulating protein induced a transphosphorylation of Met Tyr1234/Tyr12354 . These result in autophosphorylation of multiple cytoplasmic effectors; further activates a series of intracellular downstream signaling pathways, such as the retrovirus-associated DNA sequences (RAS)/extracellular signal-regulated kinase (ERK) cascade, the phosphoinositide 3-kinase (PI3K)/AKT axis, and signal transducer and activator of transcription proteins (STATs); and leads to the activation of a series of cellular processes, including proliferation, motility, morphologic changes and invasion. [4] [5] [6] Recently, researchers showed that Met is a marker for PDA stem cells. 7 Met also has critical roles in the interactions between PDA cells and fibroblasts and promotes cancer aggression and progression. 8 Furthermore, PDA cells overexpressing Met are resistant to treatment with gemcitabine and radiation. 7, 9 Elevated expression of Met in PDA cells is frequently found and correlated with poor prognosis. 10 Met can be mutated in other tumor types, but its mutation is rare in PDA cases according to the Cancer Genome Atlas database. Previous studies have demonstrated that hypoxia and expression of Neuromedin U and cytokines can lead to increased expression and activation of Met in PDA cells. [11] [12] [13] However, the mechanism of elevated expression and activation of Met in PDA cases remains unclear.
Forkhead box M1 (FOXM1) is a transcription factor in the FOX superfamily that is characterized by a conserved winged helix DNA-binding domain. 14 FOXM1 is a key regulator of cell cycle progression, and a series of studies demonstrated that FOXM1 has critical roles in epithelial-to-mesenchymal transition, invasion, metastasis, angiogenesis, and stem cell self-renewal and proliferation in PDA cases. [15] [16] [17] Recently, we have reported that FOXM1 transactivates lactate dehydrogenase A and promotes the Warburg effect and PDA progression. 18 However, the mechanism of elevated expression and the tumor-promoting role of FOXM1 in PDA cases remain to be elucidated.
In the present study, we have demonstrated that FOXM1 transcriptionally upregulates the expression of Met and has critical roles in the activation of HGF/Met signaling. Meanwhile, activation of HGF/Met signaling leads to increased expression and transcriptional activity of FOXM1 via its downstream signaling of ERK1/2, AKT and STAT3. HGF/Met and FOXM1 form a positive feedback loop which promotes PDA growth and resistance to Met inhibition RESULTS Elevated expression of Met in PDA cells and its direct association with clinicopathologic characteristics Authors have reported the tyrosine kinase Met to be overexpressed in multiple human cancers and that it drives tumor growth and metastasis. In the present study, we analyzed the expression of Met in PDA cell lines and pancreatic tumor specimens. As compared with its expression in normal human embryonic kidney 293 cells, Met mRNA and protein were markedly overexpressed in most of the PDA cell lines except for MiaPaca-2 ( Figure 1a ), which was consistent with results of a previous study. 19 We then investigated the expression of Met in a tissue microarray (TMA) as described previously. 18 The clinicopathologic characteristics of the TMA were described in Supplementary Table S1 . We found that the levels of Met expression in tumor specimens were markedly higher than those in the normal and tumor-adjacent tissue specimens ( Figure 1b ). Moreover, we observed that stronger Met expression was correlated with higher disease pT classification (Po0.001) ( Figure 1c ) and TNM stage (Po0.001) ( Supplementary Table S2) , and with increased grade of tumor differentiation (P = 0.001) ( Figure 1d ; Supplementary Table S2 ). 
Met is a direct transcriptional target of FOXM1 in PDA cells
To determine whether Met is a transcriptional target of FOXM1, we analyzed the sequence of Met promoter for the potential FOXM1binding elements 5′-TTT(G/A)AA(A/T)-3′, 5′-(C/T)TTCC(G/T)(G/T)-3′, 5′-(C/T)AAA(C/T)AA-3′, 5′-TAATCA-3′ and/or 5′-AGATTGAGTA-3′. [20] [21] [22] [23] We identified three putative FOXM1-binding elements in the Met promoter region (Figure 3b ; Supplementary Figure S2A ). We transfected PANC-1 cells with FOXM1-overexpressing plasmids and conducted a chromatin immunoprecipitation (ChIP) assay using these cells. An anti-FOXM1 antibody but not control IgG amplified a 325-bp DNA fragment of the Met promoter in the precipitates, suggesting that FOXM1 bound directly to the Met promoter (Figures 3a and b ). Conversely, knockdown of FOXM1 expression in PANC-1 and AsPC-1 cells resulted in decreased FOXM1 recruitment to Met promoter, whereas overexpression of FOXM1 in MiaPaca-2 and PANC-1 cells led to elevated FOXM1 recruitment to Met promoter (Supplementary Figure S2B ). These results demonstrated that FOXM1 bound directly to the Met promoter.
To investigate the Met transcription regulatory role of FOXM1, we generated three Met promoter reporters, pLuc-Met-1259, pLuc-Met-1069 and pLuc-Met-580 (Supplementary Figure S2A ). We cotransfected Met promoter reporters with FOXM1 expression vectors or with small interfering RNAs (siRNAs) into AsPC-1, FG, PANC-1 and CaPan-1 cells. Overexpression of FOXM1 increased the MET promoter activity, whereas knockdown of FOXM1 decreased the MET promoter activity of both pLuc-Met-1259 and pLuc-Met-1069 reporters. But altered expression of FOXM1 had little effect on the promoter activity of pLuc-Met-580 ( Figure 3c ; Supplementary Figure S2C ). Furthermore, the regulatory effect of FOXM1 on Met promoter activity of pLuc-Met-1259 and pLuc-Met-1069 were almost the same, suggesting that the major potential FOXM1binding sites in Met promoter were #1 and #2. These results demonstrated that FOXM1 bound directly to the promoter region of Met and transcriptionally regulated the expression of Met.
FOXM1 upregulates HGF/Met signaling and activates its downstream pathways
Met is autophosphorylated at Tyr1234 and Tyr1235 when binds with HGF, leading to activation of a series of intracellular downstream signaling events, including RAS/ERK, PI3K/AKT and STAT signaling. Therefore, we analyzed the effect of altered FOXM1 expression on HGF/Met downstream signaling. We transfected FG and PANC-1 cells with a FOXM1 expression vector, siRNA targeting FOXM1 (siFOXM1), or control vector and siRNA. Forty-eight hours later, we treated the cells with 20 ng/ml HGF for 1 h and then determined the phosphorylation status of signaling proteins downstream from HGF/Met using western blot. As shown in Figures 3d and e, knockdown of FOXM1 expression in FG cells led to decreased HGF-dependent phosphorylation of Met at Y1234 and Y1235 and its downstream transducers, including ERK1/2 at T202 and Y204, AKT at S473, and STAT3 at Y705. In contrast, FOXM1 overexpression increased the phosphorylation of Met and its downstream signaling targets in PANC-1 cells.
HGF/Met signaling stimulates the expression and transcriptional activity of FOXM1
Activation of RAS/ERK cascade, PI3K/AKT axis and STAT3, which are the downstream signaling pathways for HGF/Met, increases PDA cell survival, proliferation and motility via upregulation of FOXM1. [24] [25] [26] Similarly, we found that activation of HGF/Met signaling in FG and AsPC-1 cells by HGF led to increased phosphorylation of ERK1/2, AKT and STAT3 and upregulated Figure S6 ).
We next sought to determine which of the HGF/Met downstream signaling pathways had key roles in regulation of FOXM1 transcriptional activity by using ERK1/2 inhibitor FR180204, AKT inhibitor GSK690693 and STAT3 inhibitor S3I-201. We found that all three inhibitors blocked the stimulatory effect of HGF/Met signaling on FOXM1 transcriptional activity (Supplementary Figure S7) . These results demonstrated that FOXM1-upregulated HGF/Met signaling by transactivating Met and that activation of HGF/Met signaling stimulated the expression and transcriptional activity of FOXM1 via its downstream pathways, suggesting that HGF/Met and FOXM1 formed a positive feedback loop.
Cross-talk between FOXM1 and HGF/Met signaling promotes PDA growth
To assess the impact of cross talk between FOXM1 and HGF/Met signaling on PDA growth, we analyzed their effects on PDA cell colony formation in vitro and subcutaneous pancreatic tumor growth in vivo. Specifically, activation of HGF/Met signaling by HGF markedly increased FG cell colony formation, whereas knockdown of FOXM1 expression and inhibition of Met signaling abolished the effect (Supplementary Figure S8 ). For in vivo assay, we used PANC-1 cells with FOXM1 overexpression and FG cells with FOXM1 knockdown. The overexpression of FOXM1 markedly elevated Met expression in vivo and promoted tumor growth (Supplementary Figure S9A ). Conversely, FOXM1 knockdown markedly decreased Met expression and inhibited tumor growth (Supplementary Figure S9B) . These data suggested that this HGF/ Met-FOXM1 positive feedback loop promoted PDA growth.
FOXM1 mediates PDA cell resistance to Met inhibition PHA-665752 is an ATP-competitive small molecule inhibitor of Met that selectively inhibits the receptor kinase domain, disrupting the HGF/Met signaling pathway. 27 Because FOXM1 forms a positive feedback loop with HGF/Met, we investigated whether FOXM1 had any roles in mediating PDA resistance to HGF/Met signaling inhibition. We generated PANC-1 and FG sublines resistant to PHA-665752 via continuous culture in increasing concentrations of the drug. The resulting sublines, PANC-1-R and FG-R, were more resistant to PHA-665752 than the parental cell lines (half-maximal inhibitory concentrations (IC 50 ), 0.53 vs 1.47 μM (P o0.001) and 0.58 vs 1.60 μM (P o 0.001), respectively) ( Figure 5a ). Also, the PHA-665752-resistant cells had higher levels of FOXM1 and Met expression than the parental cells did (Figure 5a ; Supplementary  Figures S10A and B) . 
FOXM1 inhibition increases PDA cells' sensitivity to Met inhibition
Our findings suggested that HGF/Met and FOXM1 form a positive feedback loop and that FOXM1 promotes PDA cells' resistance to Met inhibition. We finally sought to determine whether inhibition of FOXM1 expression is an effective strategy of reversing resistance of PDA cells to Met inhibition. As shown in Figure 6a , treatment of FG-R cells with the FOXM1 inhibitor TST decreased the expression of FOXM1 in a dose-dependent manner, and pretreatment of these cells with 2 μM TST significantly sensitized them to treatment with PHA-665752 (IC 50 : 0.55, 1.56, 0.63 and 0.19 μM in FG cells and in FG-R cells pretreated with 0, 1 and 2 μM TST, respectively; P o0.001). 28 Furthermore, treatment with TST and PHA-665752 inhibited the growth of FG-R cells in a xenograft model as compared with control groups, and treatment with the combination of TST and PHA-665752 was more effective than that with either inhibitor alone (Figures 6b-d) . 
DISCUSSION
In the present study, we demonstrate for the first time that FOXM1 transcriptionally regulates the expression of Met; HGF/Met signaling stimulates the expression and transcriptional activity of FOXM1 via RAS/ERK1/2, PI3K/AKT and STAT3 signaling pathways; and HGF/Met and FOXM1 form a positive feedback loop (Figure 7) .
Our experimental and clinical evidence strongly suggest that this positive feedback loop promotes PDA growth and resistance to Met inhibition. HGF/Met signaling is aberrantly induced or activated in different solid tumors and has been associated with poor prognosis. 29 In PDAs, Met has been overexpressed and associated with clinicopathologic parameters and survival. 10 Met also promotes the growth, invasion, metastasis, drug resistance and stem cell maintenance of PDA. 29 Expression of Neuromedin U and cytokines can elevate the expression and activation of Met in PDA cells, whereas mechanism underlying aberrant activation of HGF/Met signaling requires further study. [11] [12] [13] In the present study, we systematically analyzed the Met expression patterns in PDA cell lines and tissue specimens. We found that expression of Met was markedly increased in most of PDA cell lines, and statistical analysis of the relationships of Met expression with clinicopathologic PDA parameters revealed that increased expression of Met in PDA specimens correlated with PDA progression and differentiation. Furthermore, we provided four lines of evidence supporting that FOXM1 transcriptionally upregulated the expression of Met and elevated the activation of HGF/Met signaling. First, we showed that FOXM1 and Met were concomitantly overexpressed in PDA specimens. Second, overexpression of FOXM1 increased the expression of Met at both the mRNA and protein level, whereas knockdown of FOXM1 expression did the opposite. The oncogenic transcription factor FOXM1 is a key regulator of cell cycle progression, and recent studies further established the roles of FOXM1 in promoting cancer growth, invasion, metastasis, angiogenesis, metabolism and stem cell maintenance. 15, 18, 30, 31 FOXM1 is overexpressed in PDA cells and its overexpression is associated with PDA development and progression. 15 However, the mechanism of elevated expression of FOXM1 and its promotive effect on PDA have remained unclear. In the present study, we found that FOXM1 transactivated Met and increased the activity Given the critical roles of HGF and Met in cancer development and progression, a number of HGF/Met signaling inhibitors have been generated and have antitumor effects in many preclinical animal models. However, single-agent administration of Met inhibitors had only moderate clinical benefits in treatment of cancers with HGF/Met signaling abnormalities. 6 Thus, studies of the mechanisms of resistance of PDA cells to Met inhibition are urgently needed. Previous studies demonstrated that overexpression of transforming growth factor-α led to activation of the epidermal growth factor receptor pathway and subsequent resistance to Met inhibition. 32 In the present study, we showed that PDA cells resistant to the Met inhibitor PHA-665752 had higher levels of FOXM1 and Met expression than the control cells and that FOXM1 overexpression resulted in increased resistance to PHA-665752, whereas knockdown of FOXM1 expression led to reduced resistance to it. Furthermore, treatment with FOXM1 inhibitor TST and Met inhibitor PHA-665752 inhibited the growth of PHA-665752-resistant PDA cells in vitro and in vivo, and treatment with the combination of TST and PHA-665752 was more effective than that with either inhibitor alone. Recently, investigators have analyzed many approaches targeting HGF/Met signaling, including inhibition of HGF and of Met expression with antibodies or tyrosine kinase inhibitors, mostly in phase 1 clinical trials. 29 Our present study has suggested an alternative approach to render tumor cells more sensitive to the existing inhibitors.
In summary, our results demonstrate a positive feedback loop formed by HGF/Met and FOXM1 and its role in promoting PDA growth and resistance to Met inhibition. Therefore, we have not only identified a novel molecular mechanism underlying aberrant activation of HGF/Met and FOXM1 in PDA cells, but also have revealed that the combine use of both inhibitors for FOXM1 and HGF/Met signaling is a promising therapeutic strategy for PDA.
MATERIALS AND METHODS

Cell culture and reagents
Human embryonic kidney 293 cells and the human PDA cell lines PANC-1, MiaPaCa-2, AsPC-1, BxPC-3, CaPan-1 and CaPan-2 were purchased from the American Type Culture Collection. The FG, COLO357 and L3.7 were described previously. 16 All of these cell lines were maintained in plastic flasks as adherent monolayers in Eagle's minimal essential medium supplemented with 10% fetal bovine serum, sodium pyruvate, nonessential amino acids, L-glutamine and a vitamin solution (Flow Laboratories, Rockville, MD, USA). The cell lines were obtained directly from the American Type Culture Collection, which performs cell line characterization and authentication using short tandem repeat profiling, and were passaged in our laboratory for fewer than 6 months after receipt.
The Met tyrosine kinase inhibitor PHA-665752, ERK1/2 inhibitor FR180204, AKT kinase inhibitor GSK690693, STAT3 inhibitor S3I-201, Met ligand HGF and FOXM1 inhibitor thiostrepton (TST) were obtained from Sigma-Aldrich, (St Louis, MO, USA). [33] [34] [35] To generate PDA cell lines resistant to PHA-665752, parental PANC-1 and FG cells were treated with 0.5 μM PHA-665752. The concentration of PHA-665752 was progressively increased once every 2 weeks in 0.5-μM increments up to a final concentration of 2.5 μM. PHA-665752 was replenished every 3-5 days as needed. After 4 months, the two cell lines became sufficiently resistant to PHA-665752 and were referred to as PANC-1-R and FG-R, respectively. The IC 50 of the chemoresistant sublines were determined using MTT assays.
Human tissue specimens and immunohistochemical analysis TMA construction and immunohistochemical analysis were conducted as described previously. 18 Briefly, a TMA containing primary tumor specimens from 154 patients with PDA was obtained from the PDA Tissue Bank at Shanghai Jiaotong University Affiliated First People's Hospital (Shanghai, People's Republic of China). In addition to 154 primary tumor specimens, the TMA contained 34 matched tumor-adjacent tissue specimens and 22 normal tissue specimens. The use of archived human PDA tissues was approved by MD Anderson Cancer Center institutional review board. The TMA was prepared and processed for immunostaining with anti-Met (#8198; Cell Signaling Technology, Danvers, MA, USA) and anti-FOXM1 (WH0002305M2; Sigma-Aldrich) antibodies. The staining results were scored by two investigators blinded to the clinical data as described previously. 36 
Plasmids and small interfering RNAs
The plasmid pcDNA3.1-FOXM1B (pFOXM1) and control vector plasmid pcDNA3.1 were described previously. 37 siRNAs targeting Met was synthesized by Dharmacon (Lafayette, CO, USA), and the sequence of siRNA#1 5′-GTGCAGTATCCTCTGACAG-3′ and siRNA#2 5′-AAGTGCAGTATCCTCTGACAG-3′ were reported previously. 38, 39 siFOXM1 was described previously. 40 
Transient transfection
Transfection of plasmids and siRNAs into PDA cells was performed using the transfection reagents Lipofectamine LTX and Lipofectamine 2000 CD (Invitrogen, San Diego, CA, USA), respectively. For transient transfection, cells were transfected with plasmids or siRNAs at different doses as indicated for 48 h before the performance of functional assays. PDA cells treated with a transfection reagent alone were included as mock controls. 
Quantitative real-time PCR
Quantitative real-time reverse transcription-PCR (qRT-PCR) analysis of expression of the Met and FOXM1 genes was performed using total RNA and SYBR Green reagent with an ABI Prism 7000HT sequence detection system. 41 The sequences of the qPCR primers were as follows: Met, 5′-gtttg tcacagagacttggctg-3′ (forward) and 5′-atccacttcactggcagctttg-3′ (reverse); FOXM1, 5′-acgtccccaagccaggctc-3′ (forward) and 5′-ctactgtagctcaggaataa-3′ (reverse); and glyceraldehyde-3-phosphate dehydrogenase (GAPDH), 5′-acag tccatgccatcactgcc-3′ (forward) and 5′-gcctgcttcaccaccttcttg-3′ (reverse).
Western blot analysis
Standard western blot analysis was carried out using primary anti-FOXM1 (sc-502; Santa Cruz Biotechnology (Dallas, TX, USA)), anti-Met (sc-161; Santa Cruz Biotechnology), anti-phosphorylated Met (Tyr1234/Tyr1235 (#8218); Cell Signaling Technology), anti-AKT (#9272; Cell Signaling Technology), antiphosphorylated AKT (Ser472 (#9271); Cell Signaling Technology), anti-p44/42 ERK1/2 (#9102; Cell Signaling Technology), anti-phosphorylated p44/42 ERK1/2 (Thr202/Tyr204 (#8201); Cell Signaling Technology), anti-STAT3 (#9132; Cell Signaling Technology) and anti-phosphorylated STAT3 (Tyr705 (#9135); Cell Signaling Technology) antibodies. Anti-mouse (Cell Signaling Technology) and anti-rabbit (Santa Cruz Biotechnology) antibodies were used as secondary antibodies. Equal protein-sample loading was monitored using an anti-GAPDH antibody (Santa Cruz Biotechnology). The bands were quantified using Quantity One analysis software, Version 4.6 Bio-Rad (Hercules, CA, USA) and the results of fold changes were expressed as numbers in italic font under individual blot.
Construction of the Met promoter reporter and dual luciferase assay
The promoter region of MET was delineated using the Gene2Promoter software program (Genomatix Software GmbH, Munich, Germany), and a fragment of 1259 bp containing MET 5′ sequences from − 1023 to +236 bp relative to the transcription initiation site was subcloned into the pGL3basic vector (Promega, Madison, WI, USA). The final full-length reporter plasmid, which contained multiple FOXM1-binding sites, was designated pLuc-Met-1259. The deletion mutation reporter for this plasmids, pLuc-Met-1069 and pLuc-Met-580, were then generated. All the constructs were verified by sequencing the inserts and flanking regions of the plasmids. Cyclin B1 promoter reporter was a fragment of 968 bp containing CCNB1 5′ sequences from − 931 to +37 bp relative to the transcription initiation site, and was designated pLuc-cyclin B1. PDA cells were transfected with Met promoter reporters, siFOXM1, or an expression plasmid or transfected with pFOXM1, pLuc-cyclin B1 and a FOXM1-dependent luciferase reporter (6X-FOXM1-Luc), which was described previously, 41 and treated with HGF or PHA-665752 and HGF with FR180204, GSK690693 or S3I-201. The transcriptional activity was normalized via co-transfection with a β-actin/Renilla luciferase reporter containing a full-length Renilla luciferase gene. The luciferase activity in the cells was quantified using a dual luciferase assay system (Promega) 24 h after transfection.
Chromatin immunoprecipitation assay
Pancreatic tumor cells (2 × 10 6 ) were prepared for a ChIP assay with a ChIP assay kit EMD Millipore (Billerica, MA, USA) according to the manufacturer's protocol. The resulting precipitated DNA specimens were analyzed using PCR or qPCR to amplify a 325-bp region of the Met promoter. The PCR products were resolved electrophoretically on a 2% agarose gel and visualized using ethidium bromide staining. 42 Colony formation assay A colony formation assay was performed to assess the proliferation of PDA cells. PANC-1 cells were transfected with siFOXM1 or control siRNA. Forty-eight hours later, 200 cells were plated in 24-well plates and treated with indicated groups. The media were changed every 2 days, and allowed to grow for 14 days. Cells were then fixed with 4% paraformaldehyde and stained with a 0.1% crystal violet solution for 10 min. PANC-1 Cell colonies (420 cells each) were counted using an inverted microscope at 40 × magnification. All experiments were performed in triplicate. MTT assays PDA cells were seeded at a density of 2 × 10 3 cells per well in 96-well plates. The cells were then treated with various does of PHA-665752 and TST. Seventy-two hours later, MTT (20 μl, 5 mg/l; Sigma-Aldrich) was added to each well, and the plates were continuously cultured for 4 h. Dimethyl sulfoxide (200 μl) was then added to each well. The absorbance was measured at 570 nm.
Met
Animal experiments
Pathogen-free female athymic nude mice were purchased from our institution. The animals were maintained in facilities approved by the Association for Assessment and Accreditation of Laboratory Animal Care International in accordance with the current regulations and standards of the U.S. Department of Agriculture and Department of Health and Human Services. All animal experiments were approved by the Institutional Animal Care and Use Committee. Both investigators on animal studies were blind to the group allocation and treatments in each group from start of the experiments and completion of collection of data related to the animal experimentation.
To study PDA cell growth in vivo, 1 × 10 6 PDA cells in 0.1 ml of Hank's balanced salt solution were injected subcutaneously into the right scapular region in mice. The tumor-bearing mice were killed when they became moribund or on day 35 after injection and their tumors were removed and weighed. To determine the efficacy of PHA-665752 and TST on PHA-665752 resistance PDA cell growth, 1 × 10 6 cells were injected subcutaneously into the right scapular region in mice. PHA-665752 was dissolved in L-lactate (pH 4.8) and 10% polyethylene glycol, and TST was dissolved in N,N-dimethylacetamide, polyethylene glycol 400, and Tween 80 at a 2:7:1 v/v/v ratio. Seven days later, PHA-665752 and TST were intravenously injected into mice at 15 mg/kg per day and 50 mg/kg per day, respectively, for 21 days. 27, 28 The tumor-bearing mice were killed on day 35 after injection, and their tumors were removed and weighed.
Statistical analysis
The significance of the patient specimen data was determined using the Pearson correlation coefficient. A two-tailed χ 2 test or the Fisher exact test was used to determine the significance of the differences among the covariates. All in vitro and in vivo experiments were repeated two to four times or as indicated, the data from independent experiments were presented as the mean ± s.e.m. or as indicated otherwise, and the significance of the data was determined using the Student t-test (two-tailed) or one-way analysis of variance (ANOVA). In all of the tests, P-values o0.05 were considered statistically significant. The SPSS software program (version 13.0; IBM Corporation (New York, NY, USA)) was used for statistical analysis.
